Aethlon Medical Inc. (NASDAQ: AEMD) stock surged by 1.24% at the last close whereas the AEMD stock price declines by 6.13% in the after-hours trading session. There is no recent news available regarding the change happening in AEMD share price, as of yet. Aethlon Medical is a company that focuses on the development of products which could help in the diagnosis and treatment of organ-threatening diseases. It is basically a medical device technology company.
Since there is no recent news available to understand the graph of Aethlon Medical’s stock price therefore we will look at the previous important event happened such as Aethlon Medical announced 3Q FY2021 results and issued a revised forecast on the two clinical trials currently ongoing on February 11, 2021. AEMD is building internal infrastructure to sustain its rising prospects, which include designing drugs to detect and cure diseases in oncology and infectious diseases that are life and organ-threatening and not treated by currently licensed therapies.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The effect of therapeutic exosome loss using the Aethlon Hemopurifier in combination with standard of care therapy, Keytruda, is being investigated in a clinical trial of patients with head and neck cancer. The National Institute for Dental and Craniofacial Research (NIDCR) provided AEMD a grant in August 2020 for head and neck cancer research, which will be a joint effort between Aethlon and the University of Pittsburgh’s UPMC Hillman Cancer Center. For multi-institution research, the award is worth up to $3.5 million over five years.
Financial result depicts,
The revenue history of Keytruda further demonstrates the potential of a promising pharmaceutical drug, as well as the fact that the Hemopurifier could help other cancers that are exosome-based. Merck’s most popular medication, Keytruda, delivered $11.1 billion in sales in 2019, up 55 percent from $7.2 billion in 2018. Analysts forecast that by 2025, it would have produced over $22 billion in sales, making it the best-selling drug of all time.
With the FDA having accepted a supplement to AEMD’s IDE for the Hemopurifier in viral disease to allow testing of the product in patients with SARS-CoV-2/COVID-19 in a recent feasibility trial, COVID-19 could represent yet another opportunity and road to approval for the Hemopurifier.